Panacos Pharmaceuticals, Inc.

Gaithersburg, MD 20877

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $2.32MM
First Award Date 09/15/00
Most Recent Award Date 08/15/03

Key Personnel

Last Name Name Awards Contact
Allaway Graham P Allaway 4
Salzwedel Karl Salzwedel 1
Wild Carl T. Wild 2

7 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-52
Budget: 08/15/03 - 07/31/04

DESCRIPTION (provided by applicant): While progress has been made in the discovery and development of drugs to treat HIV infection, significant problems remain, including the development of drug resistance. In order to expand treatment options and reduce the rate of resistance development, drugs that target viral replication at points other tha...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-52
Budget: 04/01/03 - 03/31/04

Description (provided by applicant): There is a pressing need for new drugs to treat HIV infection by virus strains that are resistant to the approved reverse transcriptase and protease inhibitors. Panacos Pharmaceuticals' approach to overcoming drug resistance involves identifying HIV drug candidates with novel mechanisms of action. In colla...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/02 - 12/31/02

DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is a major cause of pediatric respiratory disease, resulting in severe lower respiratory tract infection in infants, immunocompromised patients and the elderly. There are no effective antiviral therapies for this disease although an immunoprophylactic antibody is available wh...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/02 - 10/31/02

There is a pressing need for new anti-HIV drugs that are effective against strains of the virus resistant to current regimens. Panacos Pharmaceuticals is collaborating with Professor K.H. Lee of the University of North Carolina at Chapel Hill to discover such compounds by screening plant extracts for HIV inhibitors, then designing synthetic ana...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/02 - 03/31/03

DESCRIPTION (provided by applicant): Panacos Pharmaceuticals, Inc. is collaborating with Professor K.H. Lee of The University of North Carolina at Chapel Hill to discover natural products and their derivatives that inhibit HIV replication and have novel mechanisms of action. During Phase I several lead compoun...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/01 - 03/31/02

DESCRIPTION (provided by applicant): Panacos Pharmaceuticals, Inc. is collaborating with Professor K.H. Lee of The University of North Carolina at Chapel Hill to discover natural products and their derivatives that inhibit HIV replication and have novel mechanisms of action. During Phase I several lead compoun...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/00 - 06/14/01

DESCRIPTION: This is a Phase I proposal based on the potential protective immunogencity of DP-178 a 36mer peptide derived from the conserved alpha helical membrane-proximal domain of the HIV gp41 TM. This gp41 region is of interest because it is involved in membrane fusion and viral entry and the epitope...